The Antibody Drug Conjugates Market, estimated at USD 7.01 Bn in 2025, is expected to exhibit a CAGR of 14.2% and reach USD 17.76 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
The key market players are focusing on adopting growth strategies, such as collabortions, which is anticipated to drive the global antibody drug conjugates market growth over the forecasted period. For instance, in December 2025, Merck, a multinational pharmaceutical corporation, and Kelun-Biotech, a clinical-stage biotech company, announced a collaboration and exclusive licensing agreement to develop seven investigational preclinical Antibody-drug Conjugates (ADC) for cancer treatment. Kelun-Biotech has awarded Merck exclusive global licenses to research, develop, manufacture, and commercialize multiple investigational preclinical ADC therapies, as well as exclusive options to obtain further licenses to ADC candidates, under the terms of the agreement.
Global Antibody Drug Conjugates Market - Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation from one place to another.
COVID-19 had a significant impact on the global antibody drug conjugates market. According to an article published in February 2025 by American Cancer Society, there was a 52% decrease in the diagnosis of breast cancer and a 25% decrease in the diagnosis of pancreatic cancer in the U.S. between March 2020 and April 2020, as compared to January 2020 and February 2020. As a result, the pandemic affected the ongoing research and development of potential antibody drug conjugates.
Global Antibody Drug Conjugates Market: Key Developments
On July 10, 2023, BeiGene, a biotechnology company, and DualityBio, a clinical stage company, announced a collaboration in which BeiGene would acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with selected solid tumors. DualityBio will receive an upfront payment and will be eligible for additional payments based on the achievement of certain development, regulatory, and commercial milestones, totaling up to US$ 1.3 billion, in addition to tiered royalties, under the terms of the agreement.
On April 18, 2023, Sutro Biopharma, Inc., a clinical-stage oncology company, announced enhanced preclinical data for STRO-003, its ROR1 targeting ADC, presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, held from April 14-19, 2023 in Orlando, U.S. STRO-003 is a new, next-generation ADC that targets ROR1 and attaches to -glucuronide-exatecan linker-payloads via site-specific conjugation methods, achieving a drug-antibody-ratio (DAR) of eight.